Merck Collaborating on Novel COVID-19 Vaccine, Oral Antiviral

First Biologic OK'd for Pediatric Atopic Dermatitis; Hypothyroidism Treatment Recalled

Inbox

x

MPR Daily Dose <editor@email.empr.com> Unsubscribe

3:11 AM (18 hours ago)

to me

If you are having trouble viewing this email, click here.

MUST READS Dupixent Approval Expanded to Pediatric Patients With Atopic Dermatitis Superpotent Lots of Hypothyroidism Treatment NP Thyroid Recalled Merck Collaborating on Novel COVID-19 Vaccine, Oral Antiviral Galcanezumab Linked to Improved Work Productivity in Patients With Migraine Voclosporin NDA for Lupus Nephritis Submitted to FDA FEATURE Lawsuits in the Time of COVID-19: An Overview CME/CE Spotlight Improved Outcomes for Naïve & Heavily Treatment—Experienced HIV Patients AMA PRA Category 1 Credit(s)TM, CE for Pharmacists CLICK HERE FOR A FULL LIST OF COURSES CE/CME Powered By myCME